Sino Biopharmaceutical H1 2025 Financial Report

RMB 17.57 Billion in Revenue! Interim Results of Chia Tai–Tianqing’s Parent Company Disclosed

Moments ago, Sino Biopharmaceutical released its 2025 first-half results. During the reporting period: revenue was RMB 17.57 billion, up 10.7% year on year. Of this, innovative products generated RMB 7.80 billion, up 27.2%, accounting for 44.4% of total revenue. R&D investment reached RMB 3.19 billion, about 18.1% of total revenue.

Sino Biopharmaceutical Co., Ltd. and its subsidiaries span the full pharmaceutical value chain, covering R&D platforms, intelligent manufacturing, and a strong sales system. Its portfolio includes multiple biologics and chemical medicines, with leading positions across four major therapeutic areas: oncology, liver disease/metabolism, respiratory, and surgery/pain management.

Main Subsidiaries

• Chia Tai–Tianqing Pharmaceutical Group Co., Ltd.
• Beijing Tide Pharmaceutical Co., Ltd.
• Nanjing Chia Tai–Tianqing Pharmaceutical Co., Ltd.
• Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
• Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd.
• invoX Pharma Limited

In July, Sino Biopharmaceutical announced the 100% acquisition of Lixin Pharma Technology (Shanghai) Co., Ltd. (“Lixin Pharma”) for a net consideration of US$500 million.

Product Approvals

According to the announcement, during the reporting period the company had two innovative products approved for marketing by the NMPA:

• Putanning (Meloxicam Injection (II))
• Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection)

In 1H 2025, revenue from innovative products reached RMB 7.80 billion, a 27.2% year-on-year increase. In addition to innovative products, the company had five generic drugs approved by the NMPA, and overall generic-drug revenue maintained positive growth in the first half of 2025.

Outlook (Oncology)

The group stated in the announcement that over the next three years (2025–2027) it expects six innovative drugs and ten biosimilars or generic drugs to receive marketing approval in the oncology field.

Reference

[1]. https://www.sinobiopharm.com/userfiles/files/E25072517-Sino%20Bio-IR-PA.pdf